Spotlight

PQM+ recognizes the first lab in Nigeria to achieve WHO prequalification

The National Agency for Food and Drug Administration and Control (NAFDAC) Central Drug Control Laboratory (CDCL) in Nigeria recently attained World Health Organization prequalification status. This significant milestone is a first for a Nigerian laboratory, underscoring NAFDAC's commitment to medicines quality and public health. World Health Organization (WHO) prequalification brings global recognition, enhanced pharmaceutical quality, streamlined regulatory processes, and

strengthened credibility to NAFDAC and Nigeria's health care system.

The Nigerian CDCL is only the second laboratory in West Africa to attain WHO prequalification. Since 2009, the USAID-funded PQM and PQM+ programs have worked with NAFDAC to strengthen Nigeria's regulatory and quality assurance systems. This achievement culminates a decade-long journey for which NAFDAC Director-General Prof. Mojisola Adeyeye expressed gratitude to stakeholders, including the Minister of Health, NAFDAC management, CDCL staff, and partners such as the WHO Nigeria Country Office, USAIDs PQM+ Nigeria Country Office, and the Global Fund for their hard work and unwavering commitment. Learn more by clicking the link in the button below.

Learn More

Global Highlights

Interactive report highlights PQM+ impact in 2023

During 2023, PQM+ worked in 25 countries across Africa, Asia, and Latin America to sustainably strengthen medical product quality assurance systems in low- and middle-income countries. Highlights of the program's impact are available as an interactive presentation on our website, allowing users to explore some of our work in our five key results areas: improved governance, strengthened regulatory systems, increased product supply, optimized resources, and learning. The results are part of a broader global health impact report that highlights USP's programs. Check it out at the link below.

Access the Report

Efforts in Ethiopia and

PQM+ showcases

Pakistan strengthen pharmacovigilance of vaccines

USAID's Global Health: Science and Practice journal recently published an article that PQM+ staff authored, detailing the program's efforts to improve the pharmacovigilance of vaccines. The article, titled "Leveraging COVID-19 Vaccine Safety Monitoring in Ethiopia and Pakistan to Enhance System-Wide Safety Surveillance," explains how the program strengthened pharmacovigilance systems that deal with adverse events following immunization (AEFIs) to promote public confidence in COVID vaccines.

Read the Article

country case studies in USAID's HSS webinar series

As part of USAID's Health Systems Strengthening Learning Series, PQM+ hosted a webinar on promoting medical product quality assurance to achieve better health outcomes. Learn how USAID's early and long-term investments in strengthening medical product quality assurance systems are paying off continent-wide in Africa, as well as in many individual countries, with specific case-study examples from Benin, Kenya, Ghana, Mali, and Pakistan. Watch the full webinar and access other resources in link below.

Watch the Webinar



PQM+ presents latest at Scientific Conference on Medical Products Regulation in Africa

PQM+ contributed a wealth of content to the Scientific Conference on Medical Products Regulation in Africa (SCoMRA) in December 2023 in Egypt. Hosted by the African Union Development Agency (AUDA-NEPAD) and the WHO, the conference convened more than 300 policymakers, regulators, researchers, manufacturers, and other stakeholders across Africa. The conference's theme for 2023 was "strengthening regulatory systems for the advancement of local production and increased access to medical products and technologies for Africans." PQM+ joined USP's Global Health Programs in hosting two plenary sessions, four parallel sessions, and one poster of our latest work.

Access the Resources

News

New guidance resources published for National Regulatory Authorities

The “Emergency Use Authorization for Therapeutics: Guidance for National Medicine Regulatory Authorities” document is now available on our website in both English and French. This resource provides practical guidance to national regulatory authorities (NRAs) on adopting, implementing, and managing expedited approval pathways for therapeutics (drugs and non-vaccine biological products). Access the resource and watch a webinar on expedited regulatory pathways **here**.

PQM+ also developed model dossier guidance that NRAs and manufacturers can consult in seeking to use facilitated pathways for product authorization. These facilitated approaches will enable users to quickly help meet needs for new products and function optimally during public health emergencies. Access the resource **here**.

Follow us on social media!

For ongoing updates from PQM+, follow us on social media at our Twitter/X handle @USPGlobalHealth and U.S. Pharmacopeia’s page on LinkedIn.

Visit our Website